Expression of Concern: Carbetocin versus sublingual misoprostol plus oxytocin infusion for prevention of postpartum hemorrhage at cesarean section in patients with risk factors: a randomized, open trail study (Archives of Gynecology and Obstetrics, (2013), 288, 6, (1231-1236), 10.1007/s00404-013-2896-7);Carbetocin versus sublingual misoprostol plus oxytocin infusion for prevention of postpartum hemorrhage at cesarean section in patients with risk factors: A randomized, open trail study

Archives of Gynecology and Obstetrics

Volumn 288, Issue 6, 2013, Pages 1231-1236

  Elgafor El Sharkwy, Ibrahim Abd ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Carbetocin; Cesarean section; Misoprostol; Oxytocin; Postpartum hemorrhage; Prevention

Indexed keywords

CARBETOCIN; HEMOGLOBIN; MISOPROSTOL; OXYTOCIN; PLACEBO; UTEROTONIC AGENT;

ADULT; ARTICLE; BLOOD TRANSFUSION; CESAREAN SECTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; NAUSEA; OPEN STUDY; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; POSTPARTUM HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SHIVERING; SIDE EFFECT; VOMITING;

ADMINISTRATION, SUBLINGUAL; ADULT; CESAREAN SECTION; DELIVERY, OBSTETRIC; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MISOPROSTOL; OXYTOCICS; OXYTOCIN; POSTPARTUM HEMORRHAGE; PREGNANCY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84888986441     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-024-07634-8     Document Type: Erratum

References (27)

1. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367(9516):1066-1074
2. Wedisinghe L, Macleod M, Murphy DJ (2008) Use of oxytocin to prevent haemorrhage at caesarean section - a survey of practice in the United Kingdom. Eur J Obstet Gynecol Reprod Biol 137:27-30
3. American College of Obstetricians and Gynecologists (2006) ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 76, October 2006: postpartum hemorrhage. Obstet Gynecol 108(4):1039-1047
4. Bouwmeester FW, Boltc AC, van Geijn HP (2005) Pharmacological and surgical therapy for primary postpartum haemorrhage. Curr Pharm Des 11:759-773
5. United Nations. United Nations Millennium Development Goals 2000. http://www.un.org/millenniumgoals. Accessed 15 Sep 2011
6. Chong Y-S, Su L-L, Arulkumaran S (2004) Current strategies for the prevention of postpartum haemorrhage in the third stage of labour. Curr Opin Obstet Gynecol 16:143-150
7. Chard T, Boyd N, Forsling M (1970) The development of a radioimmunoassay for oxytocin: the extraction of oxytocin from plasma, and its measurement during parturition in human and goat blood. J Endocrinol 48:223-234
8. Walley RL, Wilson JB, Crane JMG, Mathews K, Sawyer E, Hutchens DA (2000) Double-blind placebo controlled randomized trial of misoprostol and oxytocin in the management of the third stage of labour. Br J Obstet Gynaecol 107:111-1115
9. Nasr A, Shahin AY, Elsamman AM, Zakherah MS, Shaaban OM (2009) Rectal misoprostol versus intravenous oxytocin for prevention of postpartum hemorrhage. Int J Gynecol Obstet 105(3):244-247
10. Tang OS, Gemzell-Danielsson K, Ho PC (2007) Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 99(Suppl 2):160-167
11. Sweeney G, Holbrook AM, Levine M et al (1990) Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Curr Ther Res 47:520-540
12. Hunter DJ, Schulz P, Wassenaar W (1992) Effect of carbetocin, a long-acting oxytocin analogue in the postpartum uterus. Clin Pharmacol Ther 52:60-67
13. Del Angel-Garcia G, Garcia-Contreras F, Constantino-Casas P et al (2006) Economic evaluation of carbetocine for the prevention of uterine atony in patients with risk factors in Mexico. Value Health 9(6):A254
14. Attilakos G, Psaroudakis D, Ash J et al (2010) Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG 117(8):929-936
15. Boucher M, Horbay GL, Griffin P, Deschamps Y, Desjardins C, Schulz M et al (1998) Double-blind randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol 18:202-207
16. Borruto F, Treisser A, Comparetto C (2009) Prevention of utilization of carbetocin for postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet 280:707-712
17. Dansereau J, Joshi AK, Helewa ME et al (1999) Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol 180:670-676
18. World Health Organization. Unedited report of the 18th Expert Committee on the selection and use of essential medicines; March 21-25 2011. Accra, Ghana. http://www.who.int/selection-medicines/Complete-UNEDITED-TRS-18th.pdf
19. Khan RU, El-Refaey H (2003) Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol 101(5 Pt 1):968-974
20. Fekih M, Jnifene A, Fathallah K, Ben Regaya L, Memmi A, Bouguizene S et al (2009) Benefit of misoprostol for prevention of postpartum hemorrhage in cesarean section: a randomized controlled trial. J Gynecol Obstet Biol Reprod (Paris) 38(7):588-593
21. Lapaire O, Schneider MC, Stotz M, Surbek DV, Holzgreve W, Hoesli IM (2006) Oral misoprostol vs intravenous oxytocin in reducing blood loss after emergency cesarean delivery. Int J Gynecol Obstet 95(1):2-7
22. Chaudhuri P, Banerjee GB, Mandal A (2010) Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss. Int J Gynecol Obstet 109(1):25-29
23. Elsedeek MS (2012) Impact of preoperative rectal misoprostol on blood loss during and after elective cesarean delivery. Int J Gynecol Obstet 118:149-152
24. Vimala N, Mittal S, Kumar S (2006) Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynecol Obstet 92(2):106-110
25. Bellad MB, Tara D, Ganachari MS, Mallapur MD, Goudar SS, Kodkany BS et al (2010) Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind randomised controlled trial. BJOG 119:975-986
26. Chaudhuri P, Biswas J, Mandal A (2012) Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women Int J Gynecol Obstet 116:138-142
27. Singh G, Radhakrishnan G, Guleria K (2009) Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. Int J Gynecol Obstet 107(2):130-134